Insider transactions

EDGAR

Prelude Therapeutics Incorporated

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-20.

Open-market purchases (code P)
4 transactions, 5,630,630 shares
Sum of shares × price per share: 24,999,997.2
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–20 of 20

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-06-09 Filed 2026-06-10Dorton Katina Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (38,000.00) — exercise price 3.94
Acquired (A)38,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

38,000.00Direct (D) No
F1
  • F1 The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0001617541-26-000005 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-10Bonita David P Director · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (38,000.00) — exercise price 3.94
Acquired (A)38,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

38,000.00Direct (D) No
F1, F2
  • F1 The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.
  • F2 Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP.
Open filing 0001572451-26-000003 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-10Babler Martin Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (38,000.00) — exercise price 3.94
Acquired (A)38,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

38,000.00Direct (D) No
F1
  • F1 The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0001435618-26-000006 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-10FRIEDMAN PAUL A Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (38,000.00) — exercise price 3.94
Acquired (A)38,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

38,000.00Direct (D) No
F1
  • F1 The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0001236927-26-000003 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-10Sandor Victor Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (38,000.00) — exercise price 3.94
Acquired (A)38,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

38,000.00Direct (D) No
F1
  • F1 The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0001620368-26-000003 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-10BAKER BROS. ADVISORS LP Director · 10% owner667, L.P. Director · 10% ownerBaker Bros. Advisors (GP) LLC Director · 10% ownerBaker Brothers Life Sciences LP Director · 10% ownerBAKER FELIX Director · 10% ownerBAKER JULIAN Director · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Non-Qualified Stock Option (right to buy) — underlying Common Stock (38,000) — exercise price 3.94
Acquired (A)38,0000—38,000Indirect (I) See FootnotesNo
F1, F2, F3, F4, F5, F6, F7, F8
  • F1 Includes 38,000 non-qualified stock options (Stock Options) exercisable solely into common stock (Common Stock) of Prelude Therapeutics Incorporated (the Issuer) granted by the Issuer to Dr. Paul C. Scherer, a full-time employee of Baker Bros. Advisors LP (the Adviser), on June 9, 2026, in his capacity as a director of the Issuer, pursuant to the Issuer's 2020 Equity Incentive Plan (the Incentive Plan). The Stock Options have a strike price of $3.94 per share, and vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders of the Issuer, subject to Dr. Scherer's continued service on the board of directors of the Issuer (the Board) through such vesting date or an earlier change in control of the Issuer. The Stock Options expire on June 8, 2036.
  • F2 Dr. Scherer serves on the Board as a representative of 667, L.P. (667) and Baker Brothers Life Sciences, L.P. (Life Sciences, and together with 667, the Funds) and their affiliates and control persons.
  • F3 After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
  • F4 The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the Adviser GP) is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds.
  • F5 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
  • F6 Pursuant to the policies of the Adviser, Dr. Scherer does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options and Common Stock issued upon exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service.
  • F7 Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock received as a result of the exercise of the Stock Options.
  • F8 The acquisition of Stock Options reported on this form represents a single grant to Dr. Scherer of 38,000 Stock Options on Table II. This grant of 38,000 Stock Options to Dr. Scherer is reported for each of the Funds as each has an indirect pecuniary interest in such securities.
Open filing 0001193125-26-265965 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-10BAKER BROS. ADVISORS LP Director · 10% owner667, L.P. Director · 10% ownerBaker Bros. Advisors (GP) LLC Director · 10% ownerBaker Brothers Life Sciences LP Director · 10% ownerBAKER FELIX Director · 10% ownerBAKER JULIAN Director · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Non-Qualified Stock Option (right to buy) — underlying Common Stock (38,000) — exercise price 3.94
Acquired (A)38,0000—38,000Indirect (I) See FootnotesNo
F1, F2, F4, F5, F6, F7, F8, F9
  • F1 Includes 38,000 non-qualified stock options (Stock Options) exercisable solely into common stock (Common Stock) of Prelude Therapeutics Incorporated (the Issuer) granted by the Issuer to Dr. Paul C. Scherer, a full-time employee of Baker Bros. Advisors LP (the Adviser), on June 9, 2026, in his capacity as a director of the Issuer, pursuant to the Issuer's 2020 Equity Incentive Plan (the Incentive Plan). The Stock Options have a strike price of $3.94 per share, and vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders of the Issuer, subject to Dr. Scherer's continued service on the board of directors of the Issuer (the Board) through such vesting date or an earlier change in control of the Issuer. The Stock Options expire on June 8, 2036.
  • F2 Dr. Scherer serves on the Board as a representative of 667, L.P. (667) and Baker Brothers Life Sciences, L.P. (Life Sciences, and together with 667, the Funds) and their affiliates and control persons.
  • F4 The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the Adviser GP) is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds.
  • F5 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
  • F6 Pursuant to the policies of the Adviser, Dr. Scherer does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options and Common Stock issued upon exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service.
  • F7 Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock received as a result of the exercise of the Stock Options.
  • F8 The acquisition of Stock Options reported on this form represents a single grant to Dr. Scherer of 38,000 Stock Options on Table II. This grant of 38,000 Stock Options to Dr. Scherer is reported for each of the Funds as each has an indirect pecuniary interest in such securities.
  • F9 After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
Open filing 0001193125-26-265965 Read from the filing’s XML Dispute this row
2026-05-01 Filed 2026-05-04Morris Charles Q Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (450,000.00) — exercise price 4.70
Acquired (A)450,000.004.70
2,115,000

Derived: shares × price per share. Exact value 2115000.0000.

450,000.00Direct (D) No
F1
  • F1 The stock option vests as to 25% of the total shares on May 1, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0001489966-26-000004 Read from the filing’s XML Dispute this row
2026-04-27 Filed 2026-04-28RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
J

Other acquisition or disposition (describe transaction)

Common Stock
Disposed (D)1,407,000——6,475,882Indirect (I) See footnotesNo
F1, F2, F3
  • F1 On April 27, 2026, RA Capital Healthcare Fund, L.P. (the Fund) entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 1,407,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 1,407,000 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share (the Pre-Funded Warrant).
  • F2 Held directly by the Fund.
  • F3 RA Capital Management, L.P. (the Adviser) is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
Open filing 0001231919-26-000422 Read from the filing’s XML Dispute this row
2026-04-27 Filed 2026-04-28RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
J

Other acquisition or disposition (describe transaction)

Derivative security: Pre-Funded Warrants (Right to Buy) — underlying Common Stock (1,407,000) — exercise price 0.0001
Acquired (A)1,407,000——1,407,000Indirect (I) See footnotesNo
F1, F4, F2, F3
  • F1 On April 27, 2026, RA Capital Healthcare Fund, L.P. (the Fund) entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 1,407,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 1,407,000 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share (the Pre-Funded Warrant).
  • F4 The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, the Fund shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the Fund, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.
  • F2 Held directly by the Fund.
  • F3 RA Capital Management, L.P. (the Adviser) is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
Open filing 0001231919-26-000422 Read from the filing’s XML Dispute this row
2026-04-21 Filed 2026-04-23Bonita David P Director · 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)1,689,1894.44
7,499,999.16

Derived: shares × price per share. Exact value 7499999.16.

11,808,945Indirect (I) See footnotesNo
F1, F2, F5
  • F1 These securities were purchased in an underwritten public offering.
  • F2 These securities are held of record by OrbiMed Private Investments VI, LP (OPI VI). OrbiMed Capital GP VI LLC (GP VI) is the general partner of OPI VI and OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VI. The Reporting Person is a member of OrbiMed Advisors. By virtue of such relationships, OrbiMed Advisors and GP VI may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI.
  • F5 Each of the Reporting Person, OrbiMed Advisors, GP VI, OrbiMed Capital and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of his or its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000462 Read from the filing’s XML Dispute this row
2026-04-21 Filed 2026-04-23Bonita David P Director · 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)1,126,1264.44
4,999,999.44

Derived: shares × price per share. Exact value 4999999.44.

1,126,126Indirect (I) See footnotesNo
F1, F4, F5
  • F1 These securities were purchased in an underwritten public offering.
  • F4 These securities are held of record by OrbiMed Genesis Master Fund, L.P. (Genesis Master Fund). OrbiMed Genesis GP LLC (Genesis GP) is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund.
  • F5 Each of the Reporting Person, OrbiMed Advisors, GP VI, OrbiMed Capital and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of his or its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000462 Read from the filing’s XML Dispute this row
2026-04-21 Filed 2026-04-23ORBIMED ADVISORS LLC Director · 10% ownerOrbiMed Capital GP VI LLC Director · 10% ownerORBIMED CAPITAL LLC Director · 10% ownerOrbiMed Genesis GP LLC Director · 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)1,689,1894.44
7,499,999.16

Derived: shares × price per share. Exact value 7499999.16.

11,808,945Indirect (I) See footnotesNo
F1, F2, F5
  • F1 These securities were purchased in an underwritten public offering.
  • F2 These securities are held of record by OrbiMed Private Investments VI, LP (OPI VI). OrbiMed Capital GP VI LLC (GP VI) is the general partner of OPI VI and OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VI. By virtue of such relationships, OrbiMed Advisors and GP VI may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI.
  • F5 This report on Form 4 is filed by OrbiMed Advisors, GP VI, OrbiMed Capital and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VI have designated a representative, David Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report on Form 4 shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000461 Read from the filing’s XML Dispute this row
2026-04-21 Filed 2026-04-23ORBIMED ADVISORS LLC Director · 10% ownerOrbiMed Capital GP VI LLC Director · 10% ownerORBIMED CAPITAL LLC Director · 10% ownerOrbiMed Genesis GP LLC Director · 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)1,126,1264.44
4,999,999.44

Derived: shares × price per share. Exact value 4999999.44.

1,126,126Indirect (I) See footnotesNo
F1, F4, F5
  • F1 These securities were purchased in an underwritten public offering.
  • F4 These securities are held of record by OrbiMed Genesis Master Fund, L.P. (Genesis Master Fund). OrbiMed Genesis GP LLC (Genesis GP) is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund.
  • F5 This report on Form 4 is filed by OrbiMed Advisors, GP VI, OrbiMed Capital and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VI have designated a representative, David Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report on Form 4 shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000461 Read from the filing’s XML Dispute this row
2026-04-21 Filed 2026-04-22BAKER BROS. ADVISORS LP Director · 10% owner667, L.P. Director · 10% ownerBaker Bros. Advisors (GP) LLC Director · 10% ownerBaker Brothers Life Sciences LP Director · 10% ownerBAKER FELIX Director · 10% ownerBAKER JULIAN Director · 10% owner
P

Open market or private purchase of non-derivative or derivative security

Derivative security: Warrants to purchase Common Stock — underlying Common Stock (114,601) — exercise price 0.0001
Acquired (A)114,6014.4399
508,816.9799

Derived: shares × price per share. Exact value 508816.9799.

1,678,273Indirect (I) See FootnotesNo
F1, F2, F3, F4, F5, F6
  • F1 667, L.P. (667) and Baker Brothers Life Sciences, L.P. (Life Sciences, and together with 667, the Funds) purchased 114,601 and 2,137,651 warrants to purchase common stock of Prelude Therapeutics Incorporated (the Issuer) (Prefunded Warrants), respectively, for $4.4399 per warrant pursuant to an underwritten public offering that closed on April 21, 2026.
  • F2 The Prefunded Warrants have no expiration date and are exercisable at an exercise price of $0.0001 per share immediately at any time at the option of the holder on a 1-for-1 basis into Common Stock to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 4.99% of the outstanding shares of Common Stock (the Maximum Percentage) immediately prior to and following such exercise.
  • F3 By written notice to the Issuer, the Funds may from time to time increase or decrease the Maximum Percentage applicable to that Fund to any other percentage not in excess of 19.99%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer.
  • F4 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
  • F5 Baker Bros. Advisors LP (the Adviser) serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the Adviser GP) is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
  • F6 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
Open filing 0001193125-26-170468 Read from the filing’s XML Dispute this row
2026-04-21 Filed 2026-04-22BAKER BROS. ADVISORS LP Director · 10% owner667, L.P. Director · 10% ownerBaker Bros. Advisors (GP) LLC Director · 10% ownerBaker Brothers Life Sciences LP Director · 10% ownerBAKER FELIX Director · 10% ownerBAKER JULIAN Director · 10% owner
P

Open market or private purchase of non-derivative or derivative security

Derivative security: Warrants to purchase Common Stock — underlying Common Stock (2,137,651) — exercise price 0.0001
Acquired (A)2,137,6514.4399
9,490,956.6749

Derived: shares × price per share. Exact value 9490956.6749.

20,105,994Indirect (I) See FootnotesNo
F1, F2, F3, F5, F6, F7
  • F1 667, L.P. (667) and Baker Brothers Life Sciences, L.P. (Life Sciences, and together with 667, the Funds) purchased 114,601 and 2,137,651 warrants to purchase common stock of Prelude Therapeutics Incorporated (the Issuer) (Prefunded Warrants), respectively, for $4.4399 per warrant pursuant to an underwritten public offering that closed on April 21, 2026.
  • F2 The Prefunded Warrants have no expiration date and are exercisable at an exercise price of $0.0001 per share immediately at any time at the option of the holder on a 1-for-1 basis into Common Stock to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 4.99% of the outstanding shares of Common Stock (the Maximum Percentage) immediately prior to and following such exercise.
  • F3 By written notice to the Issuer, the Funds may from time to time increase or decrease the Maximum Percentage applicable to that Fund to any other percentage not in excess of 19.99%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer.
  • F5 Baker Bros. Advisors LP (the Adviser) serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the Adviser GP) is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
  • F6 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
  • F7 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
Open filing 0001193125-26-170468 Read from the filing’s XML Dispute this row
2026-02-04 Filed 2026-02-05Lim Bryant David Officer: CLO, CFO, Corp Sec.
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (275,000.00) — exercise price 2.30
Acquired (A)275,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

275,000.00Direct (D) No
F1
  • F1 The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0001752888-26-000002 Read from the filing’s XML Dispute this row
2026-02-04 Filed 2026-02-05Vaddi Krishna Director · Officer: CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (837,000.00) — exercise price 2.30
Acquired (A)837,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

837,000.00Direct (D) No
F1
  • F1 The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0001824633-26-000002 Read from the filing’s XML Dispute this row
2026-02-04 Filed 2026-02-05Combs Andrew Officer: Chief Chemistry Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (230,000.00) — exercise price 2.30
Acquired (A)230,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

230,000.00Direct (D) No
F1
  • F1 The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0001825005-26-000002 Read from the filing’s XML Dispute this row
2026-02-04 Filed 2026-02-05Scherle Peggy Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (230,000.00) — exercise price 2.30
Acquired (A)230,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

230,000.00Direct (D) No
F1
  • F1 The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0001824632-26-000002 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Soleus Private Equity Fund III, L.P. Common Stock, par value $0.0001 per share1.0675,676.0004/21/2026 Filed 2026-07-08SCHEDULE 13GOpen filing 0001213900-26-076456 Dispute this row
Soleus Private Equity GP III, LLC Common Stock, par value $0.0001 per share1.0675,676.0004/21/2026 Filed 2026-07-08SCHEDULE 13GOpen filing 0001213900-26-076456 Dispute this row
Soleus PE GP III, LLC Common Stock, par value $0.0001 per share1.0675,676.0004/21/2026 Filed 2026-07-08SCHEDULE 13GOpen filing 0001213900-26-076456 Dispute this row
Soleus Capital Master Fund, L.P. Common Stock, par value $0.0001 per share4.22,702,702.0004/21/2026 Filed 2026-07-08SCHEDULE 13GOpen filing 0001213900-26-076456 Dispute this row
Soleus Capital, LLC Common Stock, par value $0.0001 per share4.22,702,702.0004/21/2026 Filed 2026-07-08SCHEDULE 13GOpen filing 0001213900-26-076456 Dispute this row
Soleus Capital Group, LLC Common Stock, par value $0.0001 per share4.22,702,702.0004/21/2026 Filed 2026-07-08SCHEDULE 13GOpen filing 0001213900-26-076456 Dispute this row
Soleus Capital Management, L.P. Common Stock, par value $0.0001 per share5.23,378,378.0004/21/2026 Filed 2026-07-08SCHEDULE 13GOpen filing 0001213900-26-076456 Dispute this row
Soleus GP, LLC Common Stock, par value $0.0001 per share5.23,378,378.0004/21/2026 Filed 2026-07-08SCHEDULE 13GOpen filing 0001213900-26-076456 Dispute this row
Levy Guy Common Stock, par value $0.0001 per share5.23,378,378.0004/21/2026 Filed 2026-07-08SCHEDULE 13GOpen filing 0001213900-26-076456 Dispute this row
RA Capital Management, L.P. Common Stock, $0.0001 par value per share9.96,477,309.0004/21/2026 Filed 2026-04-28SCHEDULE 13GOpen filing 0001346824-26-000121 Dispute this row
Peter Kolchinsky Common Stock, $0.0001 par value per share9.96,477,309.0004/21/2026 Filed 2026-04-28SCHEDULE 13GOpen filing 0001346824-26-000121 Dispute this row
Rajeev Shah Common Stock, $0.0001 par value per share9.96,477,309.0004/21/2026 Filed 2026-04-28SCHEDULE 13GOpen filing 0001346824-26-000121 Dispute this row
RA Capital Healthcare Fund, L.P. Common Stock, $0.0001 par value per share9.96,477,309.0004/21/2026 Filed 2026-04-28SCHEDULE 13GOpen filing 0001346824-26-000121 Dispute this row
ORBIMED ADVISORS LLC COMMON STOCK1612,935,071.0004/21/2026 Filed 2026-04-23SCHEDULE 13D/AAmendment 3Open filing 0000947871-26-000463 Dispute this row
ORBIMED CAPITAL GP VI LLC COMMON STOCK14.611,808,945.0004/21/2026 Filed 2026-04-23SCHEDULE 13D/AAmendment 3Open filing 0000947871-26-000463 Dispute this row
OrbiMed Genesis GP LLC COMMON STOCK1.41,126,126.0004/21/2026 Filed 2026-04-23SCHEDULE 13D/AAmendment 3Open filing 0000947871-26-000463 Dispute this row
ORBIMED CAPITAL LLC COMMON STOCK1789,500.0004/21/2026 Filed 2026-04-23SCHEDULE 13D/AAmendment 3Open filing 0000947871-26-000463 Dispute this row
Baker Bros. Advisors LP Common Stock, $0.0001 par value per share15.510,295,301.0004/20/2026 Filed 2026-04-22SCHEDULE 13D/AAmendment 5Open filing 0001104659-26-046848 Dispute this row
Baker Bros. Advisors (GP) LLC Common Stock, $0.0001 par value per share15.510,295,301.0004/20/2026 Filed 2026-04-22SCHEDULE 13D/AAmendment 5Open filing 0001104659-26-046848 Dispute this row
Julian C. Baker Common Stock, $0.0001 par value per share15.510,295,301.0004/20/2026 Filed 2026-04-22SCHEDULE 13D/AAmendment 5Open filing 0001104659-26-046848 Dispute this row
Felix J. Baker Common Stock, $0.0001 par value per share15.510,295,301.0004/20/2026 Filed 2026-04-22SCHEDULE 13D/AAmendment 5Open filing 0001104659-26-046848 Dispute this row
Vaddi Krishna Common Stock, par value $0.0001 per share13.156,745,64712/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 6Open filing 0000929638-26-000626 Dispute this row
INCYTE CORP Common Stock, par value $0.0001 per share9.94,372,124.0011/03/2025 Filed 2025-11-07SCHEDULE 13GOpen filing 0001104659-25-108459 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,598,888 filings read, dated 2004-06-14 to 2026-11-19: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201517,857
2016222,642
2017222,009
2018223,345
2019216,482
2020224,461
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,123

Filings made before the SEC required XML are listed, not extracted.

Back to Prelude Therapeutics Incorporated